We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+6.4%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$31.9M
Cap. Flow
-$34.9M
Cap. Flow %
-16.5%
Top 10 Hldgs %
55.13%
Holding
62
New
14
Increased
11
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$15.7M
2
MRK icon
Merck
MRK
+$6.7M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
EXEL icon
Exelixis
EXEL
+$3.91M
5
INMD icon
InMode
INMD
+$3.81M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$10.3M
2
HUM icon
Humana
HUM
+$9.28M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.95M
4
STRM
Streamline Health Solutions
STRM
+$7.35M
5
CALY
Callaway Golf Company
CALY
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.32%
2 Consumer Staples 3.22%
3 Technology 0.69%
4 Consumer Discretionary 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGC
26
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.25M 1.06%
295,000
+145,000
+97% +$1.28M
CVET
27
DELISTED
Covetrus, Inc. Common Stock
CVET
$2.17M 1.02%
+129,000
New +$2.26M
UNH icon
28
UnitedHealth
UNH
$383B
$2.04M 0.97%
4,000
+3,000
+300% +$1.45M
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.35B
$2.03M 0.96%
+125,000
New +$2.01M
SPY icon
30
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$1.81M 0.86%
+4,000
New +$1.78M
PDCO
31
DELISTED
Patterson Companies, Inc.
PDCO
$1.62M 0.77%
50,000
-50,000
-50% -$1.48M
HOLX
32
DELISTED
Hologic
HOLX
$1.15M 0.55%
+15,000
New +$1.08M
RDNT icon
33
RadNet
RDNT
$4.93B
$1.12M 0.53%
50,000
-60,000
-55% -$1.47M
TRLV
34
Trulieve Cannabis Corp
TRLV
$1.65B
$1.05M 0.5%
50,000
-35,000
-41% -$737K
NXGN
35
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
$1.05M 0.49%
+50,000
New +$958K
DCGO icon
36
DocGo
DCGO
$65.9M
$1.02M 0.48%
+110,000
New +$828K
DMTK
37
DELISTED
DermTech, Inc. Common Stock
DMTK
$734K 0.35%
+50,000
New +$669K
PLXS icon
38
Plexus
PLXS
$6.47B
$409K 0.19%
5,000
-37,000
-88% -$3.08M
AHCO icon
39
AdaptHealth
AHCO
$1.45B
$321K 0.15%
20,000
-105,000
-84% -$1.89M
GLD icon
40
CALL
SPDR Gold Trust
GLD
$133B
$181K 0.09%
+1,000
New +$175K
CVS icon
41
PUT
CVS Health
CVS
$134B
$101K 0.05%
+1,000
New +$105K
BAX icon
42
PUT
Baxter International
BAX
$13.8B
$78K 0.04%
+1,000
New +$83.7K
VTRS icon
43
CALL
Viatris
VTRS
$20.7B
$33K 0.02%
3,000
-7,000
-70% -$92.2K
BAX icon
44
Baxter International
BAX
$13.8B
– –
-50,000
Closed -$4.19M
BMRN icon
45
BioMarin Pharmaceuticals
BMRN
$11.7B
– –
-90,000
Closed -$7.95M
HUM icon
46
Humana
HUM
$44B
– –
-20,000
Closed -$9.28M
ITGR icon
47
Integer Holdings
ITGR
$3.42B
– –
-25,000
Closed -$2.14M
MCK icon
48
McKesson
MCK
$101B
– –
-20,000
Closed -$4.97M
CALY
49
Callaway Golf Company
CALY
$3.33B
– –
-200,000
Closed -$5.49M
OEF icon
50
PUT
iShares S&P 100 ETF
OEF
$19.9B
– –
-1,000
Closed -$425K
1
2
3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2022 Portfolio in Review

As of Q1 2022, Tamarack Advisers held 62 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tamarack Advisers withdrew a net $34.9M in Q1 2022, closing 16 positions and reducing 20 holdings. Its most notable exit was Humana, an estimated $9.28M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 84% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Tamarack Advisers opened a new position in Gilead Sciences worth $4.46M.

  • Tamarack Advisers's largest Q1 2022 buy was Gilead Sciences: 75,000 shares worth $4.46M.
  • Tamarack Advisers added most to Cigna in Q1 2022, an estimated $15.7M increase.
  • Tamarack Advisers's biggest Q1 2022 reduction was Tenet Healthcare, cutting an estimated $10.3M.
  • Tamarack Advisers fully exited Humana in Q1 2022, selling an estimated $9.28M.
  • Tamarack Advisers's ten largest holdings make up 55% of its $211M portfolio in Q1 2022.
  • Tamarack Advisers opened 14 new positions and closed 16 in Q1 2022.
  • Tamarack Advisers's portfolio value fell 13% quarter-over-quarter to $211M.

Based on Tamarack Advisers's 13F filing for Q1 2022, filed 11 May 2022.